吸收不良症候群市場規模、佔有率、成長分析、按致病原因、按診斷、按給藥途徑、按治療、按最終用戶、按地區 - 2025 年至 2032 年行業預測

吸收不良症候群市場規模預計在 2023 年達到 31 億美元，到 2032 年將達到 56.5 億美元，預計在預測期內（2025-2032 年）的複合年成長率為 6.9%。

由於生活方式、飲食習慣的改變和人口老化等因素導致吸收不良症候群的盛行率不斷上升，全球吸收不良症候群市場正在成長。此外，乳糜瀉和克隆氏症疾病的治療也導致對有效診斷和治療方案的需求不斷成長。診斷技術的顯著進步，包括增強成像技術、生物標記識別和基因檢測，大大提高了診斷吸收不良症候群的準確性和速度，使醫療保健提供者能夠及時採取干涉措施。此外，患者和醫療保健專業人員的意識提高有助於早期發現和管理病情。教育宣傳活動和資訊傳播工作使個人能夠及時尋求醫療救助，最終在治療吸收不良症候群方面取得更好的健康結果。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

吸收不良症候群市場規模（按病因和複合年成長率） (2025-2032)

• 市場概覽
• 囊腫纖維化
• 寄生蟲病
• 腸道疾病
  • 乳糜瀉
  • 其他
• 乳糖不耐症
• 惠普爾氏症
• 熱帶口炎性腹瀉
• 其他

吸收不良症候群市場規模（按診斷和複合年成長率）（2025-2032）

• 市場概覽
• 影像學檢查
  • 電腦斷層掃描
  • 經內視鏡逆行性膽胰管攝影術（ERCP）
  • 磁振造影胰造影（MRCP）
  • 腹部X光檢查
• 血液檢查
• 其他
  • 脂肪吸收不良試驗
  • 碳水化合物吸收測試
  • 席林檢驗
  • D-木糖測試
  • 膽鹽吸收試驗
  • CD-木糖呼吸檢測

吸收不良症候群市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概覽
• 口服
• 監護人

吸收不良症候群市場規模（依治療類型及複合年成長率）（2025-2032）

• 市場概覽
• 無麩質飲食
• 抗發炎藥物
• 抗生素
• 營養補充品
• 蛋白酶和脂肪酶補充劑
• 止瀉藥
• 其他

吸收不良症候群市場規模（依最終用戶和複合年成長率） （2025-2032）

• 市場概覽
• 醫院
• 學術研究所
• 製藥公司
• 營養診所
• 其他

吸收不良症候群市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

    主要企業簡介

    • 艾伯維公司（美國）
    • 阿斯特捷利康公司（英國）
    • 拜耳公司（德國）
    • 禮來公司（美國）
    • 葛蘭素史克公司（英國）
    • 輝瑞公司（美國）
    • 賽諾菲（法國）
    • 諾華公司（瑞士）
    • 默克公司（美國）
    • 帝斯曼（荷蘭）
    • 雀巢健康科學（瑞士）
    • 武田藥品工業株式會社（日本）
    • Perrigo Company plc（愛爾蘭）
    • Lupin Pharmaceuticals, Inc.（印度）
    • Mallinckrodt製藥公司（英國）
    • 克萊爾實驗室（美國）
    • 美國國家酵素公司
    • Organon & Co.（美國）
    • Ferring BV（瑞士）
    • 百特國際公司（美國）

結論和建議

Malabsorption Syndrome Market size was valued at USD 3.1 billion in 2023 and is poised to grow from USD 3.31 billion in 2024 to USD 5.65 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Malabsorption Syndrome market is witnessing growth driven by rising prevalence attributed to factors such as lifestyle changes, dietary habits, and an aging population. Conditions like celiac disease and Crohn's disease are also contributing to increased demand for effective diagnostic and treatment solutions. Notable advancements in diagnostic technologies, including enhanced imaging techniques, biomarker identification, and genetic testing, have significantly improved the accuracy and speed of diagnosing Malabsorption Syndrome, allowing healthcare providers to initiate timely interventions. Moreover, heightened awareness among patients and healthcare professionals has fostered early detection and management of symptoms. Educational campaigns and information dissemination efforts are empowering individuals to seek medical attention promptly, ultimately leading to better health outcomes in managing Malabsorption Syndrome.

Top-down and bottom-up approaches were used to estimate and validate the size of the Malabsorption Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Malabsorption Syndrome Market Segments Analysis

Global Malabsorption Syndrome Market is segmented by Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User and region. Based on Causative Diseases, the market is segmented into Cystic Fibrosis, Parasitic Diseases, Intestinal Disorders, Lactose Intolerance, Whipple's Disease, Tropical Sprue and Others. Based on Diagnosis, the market is segmented into Imaging Studies, Hematologic Tests and Other Tests. Based on Route Of Administration, the market is segmented into Oral and Parental. Based on Treatment, the market is segmented into Gluten-Free Diet, Anti-Inflammatory Drugs, Antibiotics, Nutritional Supplements, Protease And Lipase Supplements, Antidiarrheal Agents and Others. Based on End-User, the market is segmented into Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Nutrition Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Malabsorption Syndrome Market

The increasing incidence of malabsorption syndromes, driven by shifting lifestyles, dietary habits, and an aging population, has significantly heightened the need for effective diagnostic and treatment solutions. As awareness among both healthcare professionals and patients rises, along with advancements in diagnostic technologies, the early identification and management of these disorders have become more feasible. This proactive approach has positively influenced market expansion, as the demand for innovative therapies and diagnostic tools continues to grow. Overall, the combination of these factors is propelling the growth of the malabsorption syndrome market, highlighting the importance of addressing these health challenges.

Restraints in the Malabsorption Syndrome Market

A significant constraint in the Malabsorption Syndrome market arises from the intricate and varied characteristics of malabsorption disorders, which complicate accurate diagnosis and effective treatment. Economic factors, reimbursement challenges, and inconsistencies in healthcare infrastructure across different regions further impede the delivery of optimal patient care. Moreover, the elevated costs associated with advanced diagnostic technologies and specialized treatments can limit accessibility for certain groups, ultimately affecting widespread adoption and management of these conditions. This multifaceted landscape presents notable hurdles for healthcare providers and patients alike, making it challenging to address the needs of those suffering from malabsorption syndromes effectively.

Market Trends of the Malabsorption Syndrome Market

The malabsorption syndrome market is witnessing a significant trend towards personalized medicine, emphasizing tailored diagnostic and therapeutic strategies aligned with individual patient profiles. This shift is bolstered by advancements in genetic testing and biomarker identification, enabling precise interventions that address the unique causes of malabsorption issues. Furthermore, the development of novel therapeutic modalities, including biologics and gene therapies, illustrates a commitment to innovative approaches in treatment. As healthcare evolves towards more customized care, stakeholders in the malabsorption syndrome market are increasingly focusing on leveraging these advancements to enhance patient outcomes and overall market growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Malabsorption Syndrome Market Size by Causative Diseases & CAGR (2025-2032)

• Market Overview
• Cystic Fibrosis
• Parasitic Diseases
• Intestinal Disorders
  • Celiac Disease
  • Others
• Lactose Intolerance
• Whipple's Disease
• Tropical Sprue
• Others

Global Malabsorption Syndrome Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Imaging Studies
  • CT Scan
  • Endoscopic Retrograde Cholangiopancreatogram (ERCP)
  • Magnetic Resonance Cholangiopancreatography (MRCP)
  • Abdominal X-Ray
• Hematologic Tests
• Other Tests
  • Test Of Fat Malabsorption
  • Tests Of Carbohydrate Absorption
  • Schilling Test
  • D-Xylose Test
  • Test Of Bile Salt Absorption
  • C-D-Xylose Breath Test

Global Malabsorption Syndrome Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parental

Global Malabsorption Syndrome Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Gluten-Free Diet
• Anti-Inflammatory Drugs
• Antibiotics
• Nutritional Supplements
• Protease And Lipase Supplements
• Antidiarrheal Agents
• Others

Global Malabsorption Syndrome Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Academic And Research Institutes
• Pharmaceutical Companies
• Nutrition Clinics
• Others

Global Malabsorption Syndrome Market Size & CAGR (2025-2032)

• North America (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • US
  • Canada
• Europe (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Causative Diseases, Diagnosis, Route Of Administration, Treatment, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Health Science (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perrigo Company plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Klaire Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• National Enzyme Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring B.V. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations